AIM ImmunoTech Files 8-K: Regulation FD, Other Events
Ticker: AIM · Form: 8-K · Filed: Nov 27, 2024 · CIK: 946644
Sentiment: neutral
Topics: corporate-disclosure, regulation-fd, financials
TL;DR
AIM ImmunoTech dropped an 8-K covering Reg FD, other events, and financials. Check it out.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on November 27, 2024, reporting on events that occurred on November 25, 2024. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and headquartered in Ocala, Florida.
Why It Matters
This 8-K filing provides updates on AIM ImmunoTech's corporate activities, including regulatory disclosures and other significant events, which are crucial for investors to understand the company's current status and potential future developments.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc. (company) — Former company name
- November 25, 2024 (date) — Date of earliest event reported
- November 27, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Ocala, FL (location) — Principal executive offices
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of these disclosures are not provided in the provided text snippet.
What are the 'Other Events' mentioned in the filing?
The filing lists 'Other Events' as an item information, but the specific nature of these events is not detailed in the provided text.
What financial statements and exhibits are included with this 8-K?
The filing mentions 'Financial Statements and Exhibits' as an item information, but the content of these exhibits is not specified in the provided text.
When was AIM ImmunoTech Inc. formerly known as Hemispherx Biopharma Inc.?
The date of the name change from Hemispherx Biopharma Inc. to AIM ImmunoTech Inc. was June 14, 1995.
What is the principal executive office address for AIM ImmunoTech Inc.?
The principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.
Filing Stats: 675 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-11-27 16:15:29
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001493152-24-047999.txt ( ) — 267KB
- aim-20241125.xsd (EX-101.SCH) — 3KB
- aim-20241125_lab.xml (EX-101.LAB) — 33KB
- aim-20241125_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: November 27, 2024 By /s/ Thomas K. Equels Thomas K. Equels, CEO